Abstract: Background: Vitiligo is an autoimmune skin disorder in which the loss of melanocytes is mainly attributed to defective autoimmune mechanisms and, lately, there has been more emphasis on autoinflammatory mediators. Among these is the macrophage migration inhibitory factor, which is involved in many autoimmune skin diseases. However, little is known about the contribution of this factor to vitiligo vulgaris. oBjective: To determine the hypothesized role of migration inhibitory factor in vitiligo via estimation of serum migration inhibitory factor levels and migration inhibitory factor mRNA concentrations in patients with vitiligo compared with healthy controls. We also aimed to assess whether there is a relationship between the values of serum migration inhibitory factor and/ or migration inhibitory factor mRNA with disease duration, clinical type and severity in vitiligo patients. Methods: Evaluation of migration inhibitory factor serum level and migration inhibitory factor mRNA expression by ELISA and real-time PCR, respectively, were performed for 50 patients with different degrees of vitiligo severity and compared to 15 age-and gender-matched healthy volunteers as controls. results: There was a highly significant increase in serum migration inhibitory factor and migration inhibitory factor mRNA levels in vitiligo cases when compared to controls (p<0.001). There was a significant positive correlation between both serum migration inhibitory factor and migration inhibitory factor mRNA concentrations in vitiligo patients, and each of them with duration and severity of vitiligo. In addition, patients with generalized vitiligo have significantly elevated serum migration inhibitory factor and mRNA levels than control subjects. study liMitations: Small number of investigated subjects. conclusions: Migration inhibitory factor may have an active role in the development of vitiligo, and it may also be a useful index of disease severity. Consequently, migration inhibitory factor may be a new treatment target for vitiligo patients.
INTRODUCTION
Vitiligo is a common pigmentary disorder, which has profound psychological consequences and negative impact on the psychological well-being and social interactions of the patients. 1 Many studies across decades and all over the world have attempted to illustrate the pathogenesis behind it; however, the pathogenesis of vitiligo remains elusive.
2
Among different types of vitiligo, melanocyte loss is now widely believed to be an autoimmune process, and one of the strongest factors supporting an autoimmune origin of vitiligo vulgaris is its epidemiological association with other autoimmune diseases.
3,4
Many theories have been put forward, among which the autoimmune theory is the most popular one. In addition, many studies have indicated a role for both cellular and humoral immunity in the pathogenesis of vitiligo. that MIF has a critical role in innate and adaptive immunity. 7, 8 Macrophage migration inhibitory factor (MIF) is known to be involved in immune-mediated disorders, and may also play a pivotal role in many autoimmune skin diseases, such as systemic lupus erythematosus, systemic sclerosis and atopic dermatitis. 7, 9 Autoimmunity has a role in the etiology of vitiligo, and cellular immunity is also implicated in the pathogenesis of the disease. 
METHODS
This case-control study was carried out on 50 vitiligo patients with different degrees of severity. They were selected from the Dermatology Outpatient clinic, Menoufia University hospital, between October 2014 and October 2015. In addition, 15 age-and gender-matched healthy volunteers were included as controls.
Inclusion criteria:
-Newly diagnosed cases of vitiligo.
-Any patient should stop topical (2 weeks) and systemic (1 month) treatment for his/her vitiligo before joining the study.
Exclusion criteria:
-Subjects having autoimmmune / inflammatory diseases.
-Subjects with current infection or immunosuppression.
-Pregnant or lactating women.
Each individual in the study signed a written consent form approved by The Committee of Human Rights in Research of Menoufia University.
All participants in the study were subjected to:
1-Thorough history taking, stressing on onset, duration and family history of vitiligo.
2-Complete clinical examination:
a) general examination, to detect any excluding factor b) dermatological examination, to evaluate the vitiligo and to assess its severity based on VASI score. 
Statistical analysis
The data were collected, entered and processed on IBMPC Relationship between MIF serum and MIF mRNA levels with demographic and clinical criteria among vitiligo cases: Our result revealed statistically significant correlation between both MIF serum and MIF mRNA expression levels in the studied vitiligo cases with both duration of the disease (r = 0.65, P ≤0.001 and r = 0.50, P ≤0.001, respectively) and its severity (r =0.83, P ≤0.001 for both) ( Table 3 ).
The evaluated mean value of serum MIF in cases with generalized vitiligo was (36.43±21.95) and in localized vitiligo cases was (17.13 ±8.16) and this difference was considered statistically significant (P=0.01). Also, there was highly significant increase in MIF mRNA levels in patients with generalized (7.45±3.88) than in those However, the correlation between both MIF serum and MIF mRNA values in the studied vitiligo cases with other studied demographic and clinical data could not reach the level of significance.
DISCUSSION
In the field of dermatology, MIF-a known pro-inflammatory cytokine with a pleiotropic spectrum of biologic function-is believed to be a detrimental factor in many inflammatory dermatological diseases e.g. allergic and irritant contact dermatitis, atopic dermatitis, psoriasis, alopecia areata, pemphigus vulgaris, bullous pemphigoid, photoaging and tumorigenesis. 11 The suggested role of MIF in vitiligo development is based only on two studies and its exact effect is not fully certain.
In the current study, we reported that in most patients with vitiligo vulgaris, MIF serum concentrations were significantly highly elevated than in control subjects, in agreement with that of Serarslan et al. 12 and Ma et al. 10 Within the vitiligo group, this elevated MIF serum level showed significantly positive correlation with the assessed VASI score, denoting that severe form of vitiligo is associated with high values of serum MIF. Also, estimated MIF serum levels were significantly higher in generalized than in localized vitiligo, and in long standing cases than in those of short duration of the disease.
The reported significantly positive correlations between serum MIF levels and both type and severity of vitiligo confirm the result revealed by Ma et al. 10 Although Serarslan et al. agree with us regarding correlations between serum MIF levels and disease duration and type of vitiligo, they reported no association between severity of vitiligo and serum MIF levels. 12 Some differences do exist in the measurement of vitiligo lesions by different evaluators and, compared with BSA scores, VASI scores include both lesional skin and the degree of depigmentation, which may be the reason for the difference between our results and those reported by Serarslan et al.
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Graph 2: Comparison of MIF serum and MIF mRNA levels (ng/mL) between studied groups (p<0.001)
Graph 3:
Correlation between MIF mRNA levels (ng/mL) and MIF serum levels (ng/mL) in vitiligo cases (r=0.48, P ≤0.001) of TNF-α and IL-6 mRNA levels were increased in the epidermis from vitiligo biopsies. 21 Moreover, IL-6 has been shown to play an important role in melanocytic cytotoxicity, and increased serum IL-6 levels were also detected in vitiligo vulgaris patients. 22 
